Literature DB >> 8786315

Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.

W G Brodbeck1, D Liu, J Sperry, C Mold, M E Medof.   

Abstract

Decay-accelerating factor (DAF) is a cell-associated C regulatory protein that protects host cells from autologous C attack. It functions intrinsically in host cell surface membranes to rapidly dissociate autologous classical and alternative pathway C3 convertases whenever these amplifying enzymes assemble on host cell surfaces. It is composed of four contiguous approximately 70 amino acid long regions termed short consensus repeats (SCRs) that share homology with similar units in other C3 convertase regulatory proteins. It is attached to the cell surface membrane by a glycoinositol phospholipid (GPI) anchor that is added posttranslationally. In this study, we prepared rGPI-anchored DAF proteins devoid of individual SCRs. We then incorporated the GPI-anchored products into sheep erythrocyte (Esh) hemolytic intermediates and examined their abilities to intrinsically regulate classical or alternative pathway activation. We found that classical pathway C3 convertase regulatory function resides within SCR-2 and SCR-3, while alternative pathway C3 convertase regulatory function resides within SCR-2, -3, and -4. Functional comparisons of the variant DAF proteins in fluid phase C3 activation assays established that the differences reflect domain-specific interactions rather than changes in the spatial arrangement of SCRs above the cell surface. In accordance with these findings, we found that variant DAF molecules containing SCR-1, -2, and -3, but not SCR-4, function to selectively inhibit classical pathway activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786315

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.

Authors:  O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Identification of complement regulatory domains in vaccinia virus complement control protein.

Authors:  Jayati Mullick; John Bernet; Yogesh Panse; Sharanabasava Hallihosur; Akhilesh K Singh; Arvind Sahu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Solution structure of a functionally active fragment of decay-accelerating factor.

Authors:  Stanislava Uhrinova; Feng Lin; Graeme Ball; Krystyna Bromek; Dusan Uhrin; M Edward Medof; Paul N Barlow
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

4.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Authors:  Geoffrey Gifford; Vivian P Vu; Nirmal K Banda; V Michael Holers; Guankui Wang; Ernest V Groman; Donald Backos; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2019-04-08       Impact factor: 9.776

5.  Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.

Authors:  F Lin; Y Fukuoka; A Spicer; R Ohta; N Okada; C L Harris; S N Emancipator; M E Medof
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 6.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins.

Authors:  Hemendra Singh Panwar; Hina Ojha; Payel Ghosh; Sagar H Barage; Sunil Raut; Arvind Sahu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

8.  Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.

Authors:  Jennifer White; Petra Lukacik; Dirk Esser; Michael Steward; Naomi Giddings; Jeremy R Bright; Sarah J Fritchley; B Paul Morgan; Susan M Lea; Geoffrey P Smith; Richard A G Smith
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

9.  Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments.

Authors:  A Bhatia; S Blades; G Cambridge; J C Edwards
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

10.  Interaction of decay-accelerating factor with coxsackievirus B3.

Authors:  Susan Hafenstein; Valorie D Bowman; Paul R Chipman; Carol M Bator Kelly; Feng Lin; M Edward Medof; Michael G Rossmann
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.